Global Coalition for Adaptive Research Announces the Discontinued Evaluation of Apremilast in REMAP-COVID

LOS ANGELES--(BUSINESS WIRE)-- #COVID19--Global Coalition for Adaptive Research, the U.S. Sponsor of REMAP-COVID, announced that Amgen’s apremilast (Otezla) has ended evaluation in the REMAP-COVID study. Apremilast, an oral drug which inhibits the activity of PDE4 (Phosphodiesterase 4), was selected for evaluation because it was hypothesized to inhibit the inflammatory response...

Click to view original post